NL1031882A1 - Combinatietherapie voor het behandelen van obesitas of het handhaven van gewichtsverlies. - Google Patents

Combinatietherapie voor het behandelen van obesitas of het handhaven van gewichtsverlies.

Info

Publication number
NL1031882A1
NL1031882A1 NL1031882A NL1031882A NL1031882A1 NL 1031882 A1 NL1031882 A1 NL 1031882A1 NL 1031882 A NL1031882 A NL 1031882A NL 1031882 A NL1031882 A NL 1031882A NL 1031882 A1 NL1031882 A1 NL 1031882A1
Authority
NL
Netherlands
Prior art keywords
weight loss
combination therapy
treating obesity
maintaining weight
maintaining
Prior art date
Application number
NL1031882A
Other languages
English (en)
Other versions
NL1031882C2 (nl
Inventor
Terrell Ann Patterson
Andrew Gordon Swick
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NL1031882A1 publication Critical patent/NL1031882A1/nl
Application granted granted Critical
Publication of NL1031882C2 publication Critical patent/NL1031882C2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NL1031882A 2005-05-27 2006-05-24 Combinatietherapie voor het behandelen van obesitas of het handhaven van gewichtsverlies. NL1031882C2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68575205P 2005-05-27 2005-05-27
US68575205 2005-05-27
US69751605P 2005-07-07 2005-07-07
US69751605 2005-07-07

Publications (2)

Publication Number Publication Date
NL1031882A1 true NL1031882A1 (nl) 2006-11-28
NL1031882C2 NL1031882C2 (nl) 2007-07-24

Family

ID=37097827

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1031882A NL1031882C2 (nl) 2005-05-27 2006-05-24 Combinatietherapie voor het behandelen van obesitas of het handhaven van gewichtsverlies.

Country Status (12)

Country Link
US (1) US20060270655A1 (nl)
EP (1) EP1890767A2 (nl)
JP (1) JP2008542255A (nl)
AR (1) AR053736A1 (nl)
CA (1) CA2609783A1 (nl)
DO (1) DOP2006000122A (nl)
GT (1) GT200600220A (nl)
NL (1) NL1031882C2 (nl)
PE (1) PE20070023A1 (nl)
TW (1) TW200716225A (nl)
UY (1) UY29567A1 (nl)
WO (1) WO2006129193A2 (nl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
EP1948163A2 (en) * 2005-10-18 2008-07-30 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
WO2008072061A1 (en) * 2006-12-14 2008-06-19 Pfizer Products Inc. Method of treatment of obesity with an mtp inhibitor in conjunction with an increased-fat diet
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
CA2733569A1 (en) * 2008-08-11 2010-02-18 Abunda Nutrition Inc. Diacylglycerol rich fats, oils and functional foods
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
NZ595789A (en) 2009-04-29 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2015237275B2 (en) 2014-03-27 2020-12-17 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
US10945974B2 (en) 2015-06-01 2021-03-16 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
EP3356833A4 (en) 2015-09-30 2019-04-10 Bird Rock Bio, Inc. ANTIBODIES FOR BINDING HUMAN CANNABINOID RECEPTOR 1 (CB1)
AU2017368074A1 (en) 2016-11-30 2019-06-13 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US5286647A (en) * 1982-05-21 1994-02-15 University Of California Human-human hybridomas for neoplasms
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4453913A (en) * 1982-05-21 1984-06-12 The Cadre Corporation Recuperative burner
US4540458A (en) * 1982-05-24 1985-09-10 Eastman Kodak Company Adhesive binding method for seriatim fed sheets
US4473425A (en) * 1982-05-24 1984-09-25 Eastman Kodak Company Binding apparatus and method
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5646182A (en) * 1992-06-15 1997-07-08 Burzynski; Stanislaw R. Methods for treating autoimmune diseases
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE69519995T2 (de) * 1994-10-27 2001-08-23 Janssen Pharmaceutica Nv Apolipoprotein-b syntheseinhibitoren
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
IL116148A (en) * 1994-11-30 2001-03-19 Rhone Poulenc Agrochimie Complexible composition for insect control
DE4443892A1 (de) * 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
TW457240B (en) * 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
DE69529849T2 (de) * 1995-06-07 2003-09-04 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
DE19525028A1 (de) * 1995-07-10 1997-01-16 Bayer Ag Amide und Sulfonamide von heterocyclisch substituierten Benzylaminen
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
DE19536378A1 (de) * 1995-09-29 1997-04-03 Bayer Ag Heterocyclische Aryl-, Alkyl- und Cycloalkylessigsäureamide
US5929001A (en) * 1995-10-11 1999-07-27 University Of Chicago Engineered flux-pinning centers in BSCCO TBCCO and YBCO superconductors
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
DE19546919A1 (de) * 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
CA2245586A1 (en) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
US6774236B1 (en) * 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
DE19613550A1 (de) * 1996-04-04 1997-10-09 Bayer Ag Neue Pyrimido[1,2-a]indole
DE19619950A1 (de) * 1996-04-17 1997-10-23 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide
DE19615119A1 (de) * 1996-04-17 1997-10-23 Bayer Ag Neue Arylessigsäureamide
EP0802192A1 (de) * 1996-04-17 1997-10-22 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung
DE19615262A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
DE19615263A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
US5962440A (en) * 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US6057339A (en) * 1996-05-09 2000-05-02 Bristol-Myers Squibb Company Method of inhibiting or treating phytosterolemia with an MTP inhibitor
US5827875A (en) * 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) * 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
JPH09326437A (ja) * 1996-06-06 1997-12-16 Sony Corp 複合誘電膜および半導体装置
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
AU716151B2 (en) * 1996-11-27 2000-02-17 Pfizer Inc. Apo B-secretion/MTP inhibitory amides
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
AU5513298A (en) * 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) * 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5721279A (en) * 1997-01-27 1998-02-24 The Dow Chemical Company Manufacture of cation exchange resins by pressurized sulfonation
US5837733A (en) * 1997-02-26 1998-11-17 Wisconsin Alumni Research Foundation Method for reducing secetion of apolipoprotein B in animals by administering conjugated linoleic acid
US5959498A (en) * 1997-03-03 1999-09-28 National Semiconductor Corporation Chopper-stabilized operational amplifier including low-noise chopper switch
EP0999208A4 (en) * 1997-05-30 2001-08-08 Meiji Seika Kaisha NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
WO1999022738A1 (en) * 1997-11-03 1999-05-14 Janssen Pharmaceutica N.V. Compositions of lipid lowering agents
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
IL141769A0 (en) * 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
CA2355822A1 (en) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. S-oxide lipid lowering compounds
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
KR20020005662A (ko) * 1999-04-09 2002-01-17 기따자또 이찌로 질소함유 복소환화합물 및 벤즈아미드화합물 및 그 것을함유해서 되는 의약
DE19933926A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
IL139449A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
EP1259484B1 (en) * 2000-01-18 2005-05-18 Novartis AG Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
SK287074B6 (sk) * 2000-03-23 2009-11-05 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty, spôsoby ich prípravy, medziprodukty a ich použitie
KR100575944B1 (ko) * 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP4286146B2 (ja) * 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
BRPI0410289A (pt) * 2003-05-07 2006-05-16 Pfizer Prod Inc ligantes do receptor de canabinóides e suas utilizações
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

Also Published As

Publication number Publication date
US20060270655A1 (en) 2006-11-30
WO2006129193A3 (en) 2007-03-01
GT200600220A (es) 2006-12-26
WO2006129193A2 (en) 2006-12-07
DOP2006000122A (es) 2006-11-30
EP1890767A2 (en) 2008-02-27
NL1031882C2 (nl) 2007-07-24
JP2008542255A (ja) 2008-11-27
UY29567A1 (es) 2006-12-29
PE20070023A1 (es) 2007-02-09
TW200716225A (en) 2007-05-01
CA2609783A1 (en) 2006-12-07
AR053736A1 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
NL1031882A1 (nl) Combinatietherapie voor het behandelen van obesitas of het handhaven van gewichtsverlies.
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
HK1221956A1 (zh) 用於治療感染的鹵代類苯酞化硼
NL1034928A1 (nl) Systeem voor het functioneel behandelen van wafelspanning.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
NL1031359A1 (nl) Werkwijzen en systemen voor het bewaken van tumorbelasting.
GB0602357D0 (en) Authentication of cheques and the like
GB0503684D0 (en) Emulsifiers and emulsions
IL192107A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
WO2008144223A3 (en) Triazolyl aminopyrimidine compounds
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
NL1030418A1 (nl) Azabenzoxazolen voor de behandeling van CZS-stoornissen.
NL1033562A1 (nl) Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie.
PL381862A1 (pl) Zastosowanie związków pirydyniowych i sposób leczenia
WO2010141811A3 (en) Compounds and methods for treating bone disorders and controlling weight
NL1029418A1 (nl) Behandeling van koolwaterstoffen.
IL186021A0 (en) Oxaprozin or closely related compound for the treatment and prevention of pruritus
NL1032552C2 (nl) Imidazoolverbindingen voor de behandeling van neurologische stoornissen.
WO2008144222A3 (en) Triazolyl aminopyrimidine compounds
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
NL1032065A1 (nl) Preparaat voor de preventie en behandeling van cardiovasculaire stoornissen.
NL1030417A1 (nl) Azabenzoxazolen voor de behandeling van aandoeningen van het CZS.
EP1841457A4 (en) TARGET APHERESIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
NL1028597A1 (nl) Formamidederivaten voor de behandeling van ziekten.

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20070322

PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20091201